Adipositas - Ursachen, Folgeerkrankungen, Therapie 2017; 11(02): 108-118
DOI: 10.1055/s-0037-1618955
Übersichtsarbeit
Schattauer GmbH

Improvement of comorbidity – Liraglutide 3.0 mg in patients with obesity

Article in several languages: deutsch | EnglishJ. Aberle1
  • 1Sektion Endokrinologie und Diabetologie, Universitäres Adipositas Zentrum Hamburg
Further Information

Publication History

Publication Date:
29 December 2017 (online)

Summary

Overweight is very common in adults in Germany. Especially obesity with a BMI from 30 kg/m2 onwards is associated with numerous comorbidities, e.g. diabetes or disorders of blood glucose regulation, cardiovascular diseases (e.g. hypertension, CHD), dislipidaemias, sleep apnoea and different tumours. Last but not least, obesity reduces the quality of life (especially physical quality of life), reduces the overall life expectation and increases mortality. In the treatment cascade for weight loss (lifestyle intervention, supportive pharmacological treatment, bariatric surgery ), supportive pharmacological treatment plays an important role. Liraglutide 3.0 mg once daily can increase satiety, thus reduce food intake and promote weight loss. Liraglutide 3.0 mg daily (in addition to diet and increased physical exercise) helped patients with obesity and overweight patients with overweight-related comorbidity to achieve a weight loss that was significantly superior to placebo in the primary efficacy studies (SCALE). Weight loss was higher with liraglutide compared with placebo in all groups analysed. Moreover, patients on liraglutide 3.0 mg were more frequently able to maintain a weight loss achieved prior to the start of treatment. Sleep apnoea, one of the conditions associated with overweight, was improved by liraglutide 3.0 mg. In addition to weight loss, liraglutide 3.0 mg was shown to improve several comorbidities as demonstrated by the analysis of secondary efficacy parameters (blood glucose regulation, systolic blood pressure, high-sensitivity C-reactive protein and plasminogen activator inhibitor 1). Liraglutide 3.0 mg is an option for weight loss, which – in addition to weight loss – may also improve comorbidities.